Lipomics to Develop Dxs for Metabolic Diseases in Alliance With UCD | GenomeWeb
NEW YORK (GenomeWeb News) — Lipomics and the University of California, Davis will study metabolic diseases with “an emphasis on personalized medicine,” the company said today.
 
Lipomics uses bioinformatics and other analytical tools to develop profiles of lipid metabolites it can use to develop diagnostics for metabolic diseases.  
 
Under the agreement, Lipomics will retain “certain rights to develop diagnostic applications based on the data from the studies,” the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.